Stealth Peptides Inc. Release: Bendavia Presented at 2011 American Heart Association’s Cardiovascular Scientific Sessions

Published: Aug 01, 2011

BOSTON--(BUSINESS WIRE)--Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs, presented its lead clinical candidate, Bendavia™, during the 2011 American Heart Association’s (AHA) Cardiovascular Scientific Sessions. Bendavia is a novel compound that targets the mitochondrion to treat mitochondrial dysfunction including ischemia reperfusion and microvascular injuries. AHA is a U.S. non–profit organization that focuses on cardiac care worldwide with a goal of reducing morbidity and mortality caused by cardiovascular disease, the leading cause of death worldwide. The 2011 AHA Cardiovascular Scientific Sessions were held July 18th through 21st, in New Orleans, Louisiana, and centered on state–of–the art scientific advances for cardiovascular medicine and biology.

Back to news